Overview

A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With HDM-Induced Allergic Rhinitis and/or Atopic Asthma

Status:
Completed

Trial end date:
2016-06-01

Target enrollment:

Participant gender:

Summary

To demonstrate superiority of ALK HDM tablets versus placebo in immune response, measured as change of D.farinae specific immunoglobulin G4 (IgG4) from baseline to end of treatment with ALK HDM tablets given once daily over 60 days.

Phase:

Phase 3

Details

Lead Sponsor:

Abbott

Collaborators:

Datamap
Linical Co., Ltd.